• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    4/18/22 1:32:28 PM ET
    $ADXN
    $AZYO
    $BBI
    $FREQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ADXN alert in real time by email

     

    Gainers

    • Natus Medical (NASDAQ:NTUS) shares rose 28.8% to $33.55 during Monday's regular session. The current volume of 3.0 million shares is 2073.2% of Natus Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.1 billion.
    • Frequency Therapeutics (NASDAQ:FREQ) stock moved upwards by 27.39% to $1.86. As of 13:30 EST, this security is trading at a volume of 4.8 million shares, making up 1239.5% of its average full-day volume over the last 100 days. The company's market cap stands at $65.0 million.
    • Imara (NASDAQ:IMRA) stock rose 16.34% to $1.21. The current volume of 1.6 million shares is 443.0% of Imara's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $31.8 million.
    • Brickell Biotech (NASDAQ:BBI) shares increased by 15.63% to $0.34. Trading volume for Brickell Biotech's stock is 14.2 million as of 13:30 EST. This is 181.1% of its average full-day volume over the last 100 days. The company's market cap stands at $40.9 million.
    • Aziyo Biologics (NASDAQ:AZYO) shares rose 15.27% to $7.47. The market value of their outstanding shares is at $101.2 million.
    • Addex Therapeutics (NASDAQ:ADXN) stock rose 14.2% to $5.01. The market value of their outstanding shares is at $31.6 million.

     

    Losers

    • Nutex Health (NASDAQ:NUTX) stock declined by 32.5% to $4.93 during Monday's regular session. Nutex Health's stock is trading at a volume of 610.7K shares as of 13:30 EST. This is 79.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.1 billion.
    • Nektar Therapeutics (NASDAQ:NKTR) shares declined by 27.36% to $4.47. Trading volume for this security as of 13:30 EST is 13.0 million, which is 403.0% of its average full-day volume over the last 100 days. The company's market cap stands at $833.5 million.
    • InVivo Therapeutics Hldg (NASDAQ:NVIV) shares decreased by 24.05% to $0.23. Trading volume for this security as of 13:30 EST is 1.6 million, which is 320.2% of its average full-day volume over the last 100 days. The company's market cap stands at $7.8 million.
    • TG Therapeutics (NASDAQ:TGTX) stock decreased by 21.02% to $6.99. TG Therapeutics's stock is trading at a volume of 11.4 million shares as of 13:30 EST. This is 452.3% of its average full-day volume over the last 100 days. The company's market cap stands at $998.2 million.
    • Healthcare Triangle (NASDAQ:HCTI) shares decreased by 18.86% to $0.92. The company's market cap stands at $32.3 million.
    • Revelation Biosciences (NASDAQ:REVB) stock decreased by 17.9% to $0.78. Trading volume for this security as of 13:30 EST is 406.8K, which is 15.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $AZYO
    $BBI
    $FREQ

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    TG Therapeutics Inc.
    $TGTX
    10/6/2025$60.00Buy
    H.C. Wainwright
    TG Therapeutics Inc.
    $TGTX
    7/10/2025$37.00Neutral
    Goldman
    Nektar Therapeutics
    $NKTR
    6/24/2025$60.00 → $100.00Buy
    BTIG Research
    Nektar Therapeutics
    $NKTR
    6/24/2025$6.50 → $120.00Buy
    H.C. Wainwright
    Nektar Therapeutics
    $NKTR
    4/11/2025$2.00Hold → Buy
    Jefferies
    Nektar Therapeutics
    $NKTR
    3/14/2025$6.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $ADXN
    $AZYO
    $BBI
    $FREQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Nektar Therapeutics with a new price target

    Citigroup initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $102.00

    11/26/25 8:36:15 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on TG Therapeutics with a new price target

    H.C. Wainwright resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $60.00

    10/6/25 8:31:23 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AZYO
    $BBI
    $FREQ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for UKONIQ

    Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

    2/9/21 12:05:59 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AZYO
    $BBI
    $FREQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Healthcare Triangle, Inc. Announces Approval of $2 Million Share Repurchase Plan

    PLEASANTON, Calif., March 11, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announces that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase up to $2,000,000 of its outstanding common stock ("2026 Share Repurchase Plan"). The 2026 Share Repurchase Plan was approved by the Company's Board of Directors on March 9, 2026, and became effective immediately. Under the newly authorized plan, the Company may repurchase shares of its common stock from tim

    3/11/26 4:10:00 PM ET
    $HCTI
    EDP Services
    Technology

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, March 6, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on February 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 4,300 shares of its common stock to three newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of

    3/6/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

    NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2026 annual meeting, being held April 18 - 22, 2026, in Chicago, Illinois. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below. TG PRESENTATIONS: Poster Presentation Title: Real World Clinical Experience from ENABLE, the First Phase 4 Observational Study for Patien

    3/6/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AZYO
    $BBI
    $FREQ
    SEC Filings

    View All

    SEC Form 8-K filed by Healthcare Triangle Inc.

    8-K - Healthcare Triangle, Inc. (0001839285) (Filer)

    3/11/26 4:30:29 PM ET
    $HCTI
    EDP Services
    Technology

    SEC Form S-8 filed by Nutex Health Inc.

    S-8 - Nutex Health Inc. (0001479681) (Filer)

    3/10/26 11:35:55 AM ET
    $NUTX
    Real Estate

    SEC Form SCHEDULE 13G filed by Nektar Therapeutics

    SCHEDULE 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/6/26 10:05:20 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AZYO
    $BBI
    $FREQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Nutex Health Inc.

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/11/26 6:27:50 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Nutex Health Inc.

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/11/26 6:08:03 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Nutex Health Inc.

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/11/26 5:52:21 PM ET
    $NUTX
    Real Estate

    $ADXN
    $AZYO
    $BBI
    $FREQ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    4/14/25 4:30:48 PM ET
    $NUTX
    Real Estate

    Chief Financial Officer Bates Jon Christian bought $28,970 worth of shares (1,350 units at $21.46), increasing direct ownership by 146% to 2,277 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    8/26/24 11:54:30 AM ET
    $NUTX
    Real Estate

    $ADXN
    $AZYO
    $BBI
    $FREQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/14/24 7:45:34 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 12:17:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nutex Health Inc.

    SC 13G - Nutex Health, Inc. (0001479681) (Subject)

    11/14/24 11:02:17 AM ET
    $NUTX
    Real Estate

    $ADXN
    $AZYO
    $BBI
    $FREQ
    Leadership Updates

    Live Leadership Updates

    View All

    Addex Appoints Bank of New York Mellon as Depositary Bank

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025.  The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a

    9/23/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER

    HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments  in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Wesley Bamburg as the Company's Chief Operating Officer, effective October 13, 2025. Mr. Bamburg is an accomplished healthcare executive with 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Mr. Bamburg has served as Chief Operating Officer for HCA Houst

    9/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

    5/23/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AZYO
    $BBI
    $FREQ
    Financials

    Live finance-specific insights

    View All

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care